CANBRIDGE PHARM.DL-00001 (MF1) — Tangible Net Worth Ratio
CANBRIDGE PHARM.DL-00001 (MF1) has a Tangible Net Worth Ratio of 77.9% as of December 2022. This metric is calculated by deducting intangible assets (€68.13 Million) from net assets (€308.56 Million) and expressing it as a percentage of total net assets. A higher ratio means that more of the company's equity is backed by tangible, balance-sheet-verifiable assets rather than goodwill, patents, or brand value. Also explore net asset momentum of CANBRIDGE PHARM.DL-00001 to track the company's year-over-year net asset growth rate.
Tangible NW Ratio
Net Assets (Equity)
Intangible Assets
Total Assets
CANBRIDGE PHARM.DL-00001 Tangible Net Worth Ratio (2021–2022)
This chart shows how CANBRIDGE PHARM.DL-00001's Tangible Net Worth Ratio has changed across 2 annual periods from 2021 to 2022. As of December 2022, the ratio stands at 77.9%, reflecting net assets of €308.56 Million with intangible assets of €68.13 Million EUR. For live market cap and overall valuation, see CANBRIDGE PHARM.DL-00001 market cap and net worth.
Annual Tangible Net Worth Ratio for CANBRIDGE PHARM.DL-00001 (2021–2022)
The table below presents the year-by-year Tangible Net Worth Ratio for CANBRIDGE PHARM.DL-00001 from 2021 to 2022, covering 2 annual filings. Each row shows net assets, intangible assets, total assets, the tangible net worth ratio, and the change in percentage points versus the prior year. See CANBRIDGE PHARM.DL-00001 free cash flow to debt ratio to measure the company's free cash flow as a share of total liabilities.
| Year | Tangible NW Ratio | Net Assets (EUR) | Intangible Assets | Total Assets | Change (pp) |
|---|---|---|---|---|---|
| 2022 | 77.9% | €308.56 Million | €68.13 Million | €702.04 Million | ▼ -14.7 pp |
| 2021 | 92.6% | €693.39 Million | €51.27 Million | €892.52 Million | — |